[go: up one dir, main page]

ECSP10010188A - Productos quimioterapéuticos cristalinos derivados de indazol - Google Patents

Productos quimioterapéuticos cristalinos derivados de indazol

Info

Publication number
ECSP10010188A
ECSP10010188A EC2010010188A ECSP10010188A ECSP10010188A EC SP10010188 A ECSP10010188 A EC SP10010188A EC 2010010188 A EC2010010188 A EC 2010010188A EC SP10010188 A ECSP10010188 A EC SP10010188A EC SP10010188 A ECSP10010188 A EC SP10010188A
Authority
EC
Ecuador
Prior art keywords
indazol
therapeutic products
chemical therapeutic
crystal chemical
crystal
Prior art date
Application number
EC2010010188A
Other languages
English (en)
Inventor
Thomas B Borchardt
Alexander Chu-Kung
Michael J Rozema
Shailendra V Bordawekar
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40090209&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010188(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of ECSP10010188A publication Critical patent/ECSP10010188A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Forma cristalina 1 de N-[4-(3-amino-1H-indazol-4-il)fenil]-N'-(2-fluoro-5-metilfenil)urea hidrato, maneras para elaborarla, formulaciones que comprenden a la misma y elaboradas con la misma y métodos de tratamiento de pacientes que padecen una enfermedad para usarla.
EC2010010188A 2007-10-19 2010-05-18 Productos quimioterapéuticos cristalinos derivados de indazol ECSP10010188A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98123607P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
ECSP10010188A true ECSP10010188A (es) 2010-06-29

Family

ID=40090209

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010188A ECSP10010188A (es) 2007-10-19 2010-05-18 Productos quimioterapéuticos cristalinos derivados de indazol

Country Status (24)

Country Link
US (2) US7947843B2 (es)
EP (1) EP2195298B1 (es)
JP (1) JP5517940B2 (es)
KR (1) KR20100085116A (es)
CN (1) CN101827822B (es)
AR (1) AR068917A1 (es)
AU (1) AU2008312529A1 (es)
BR (1) BRPI0818065A8 (es)
CA (1) CA2699352C (es)
CL (1) CL2008003090A1 (es)
CO (1) CO6280481A2 (es)
CR (1) CR11388A (es)
DO (1) DOP2010000115A (es)
EC (1) ECSP10010188A (es)
ES (1) ES2460951T3 (es)
MX (1) MX2010004286A (es)
PA (1) PA8800201A1 (es)
PE (1) PE20091385A1 (es)
RU (1) RU2010119928A (es)
SG (1) SG185327A1 (es)
TW (1) TW200934485A (es)
UA (1) UA99746C2 (es)
UY (1) UY31407A1 (es)
WO (1) WO2009052226A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947843B2 (en) * 2007-10-19 2011-05-24 Abbott Laboratories Crystalline chemotherapeutic
US8759538B1 (en) 2013-06-13 2014-06-24 Abbvie Inc. Crystalline chemotherapeutic

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0410745A (pt) * 2003-05-22 2006-06-27 Abbott Lab inibidores de indazol, benzisoxazol e benzisotiazol quinase
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
WO2007015569A1 (ja) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
US9006240B2 (en) * 2005-08-02 2015-04-14 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
EP1959926A1 (en) 2005-10-25 2008-08-27 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
EP1962803A1 (en) * 2005-12-23 2008-09-03 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
EP2089003A1 (en) * 2006-11-09 2009-08-19 Abbott GmbH & Co. KG Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
US7947843B2 (en) * 2007-10-19 2011-05-24 Abbott Laboratories Crystalline chemotherapeutic

Also Published As

Publication number Publication date
PE20091385A1 (es) 2009-11-12
KR20100085116A (ko) 2010-07-28
US20090118344A1 (en) 2009-05-07
UA99746C2 (ru) 2012-09-25
AR068917A1 (es) 2009-12-16
UY31407A1 (es) 2009-05-29
ES2460951T3 (es) 2014-05-16
CN101827822B (zh) 2013-06-19
PA8800201A1 (es) 2009-05-15
CN101827822A (zh) 2010-09-08
EP2195298A1 (en) 2010-06-16
WO2009052226A1 (en) 2009-04-23
JP5517940B2 (ja) 2014-06-11
DOP2010000115A (es) 2010-10-15
CA2699352C (en) 2016-06-21
US8486988B2 (en) 2013-07-16
CA2699352A1 (en) 2009-04-23
US20110196010A1 (en) 2011-08-11
TW200934485A (en) 2009-08-16
AU2008312529A1 (en) 2009-04-23
BRPI0818065A8 (pt) 2016-03-08
SG185327A1 (en) 2012-11-29
BRPI0818065A2 (pt) 2015-03-31
MX2010004286A (es) 2010-04-30
CO6280481A2 (es) 2011-05-20
CR11388A (es) 2010-10-05
US7947843B2 (en) 2011-05-24
JP2011500705A (ja) 2011-01-06
EP2195298B1 (en) 2014-02-19
RU2010119928A (ru) 2011-11-27
CL2008003090A1 (es) 2009-11-27

Similar Documents

Publication Publication Date Title
CY1115180T1 (el) Επιλογες θεραπειας για τη νοσο του fabry
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
CY1112067T1 (el) Χρηση φλιμπανσερινης για την θεραπεια διαταραχων προ-εμμηνοπαυσιακης σεξουαλικης επιθυμιας
CY1112429T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
CY1120433T1 (el) Θεραπεια αγωνιστων μελατονινης
CY1110369T1 (el) Νεος συνεργιστικος συνδυασμος ο οποιος περιεχει ροφλουμιλαστη και φορμοτερολη
DOP2010000112A (es) Productos quimioterapeuticos cristalinos
DOP2010000111A (es) Productos quimioterapeuticos cristalinos
GT200600409A (es) Uso de agomelatina para obtener medicamentos propuestos para el tratamiento de trastornos del sueño en el paciente deprimido.
DOP2010000113A (es) Productos quimioterapeuticos cristalinos
ECSP10010188A (es) Productos quimioterapéuticos cristalinos derivados de indazol
EA201000739A1 (ru) Новое медицинское применение солей 3-(2,2,2-триметилгидразиниум)пропионата
PT1631291E (pt) Uso de inibidores tirosina quinase no tratamento de diabetes
PA8624501A1 (es) Piperazinas derivadas de úrea para el tratamiento de la endometrosis